Drugs / KIF20A
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01069653 | Feb 2010 → Mar 2019 | small cell lung carcinoma | Shiga University | Completed | No outcome recorded |
| Phase 1 | NCT01069575 | Feb 2010 → Mar 2019 | non-small cell lung carcinoma | Shiga University | Completed | No outcome recorded |
| Phase 1 | NCT01259505 | Dec 2009 → Jun 2012 | breast cancer | Tokyo Medical University | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01950156 | Sep 2011 → Mar 2019 | non-small cell lung carcinoma | Shiga University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KIF20A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01069653 ↗ |
| Modality | Peptide | “KIF20A peptide” NCT01069575 ↗ |
| Route | Subcutaneous | “the HLA-A*2402-restricted CDCA1 peptide (1mg) and KIF20A peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection” NCT01069653 ↗ |
| Target | KIF20A | “URLC10, CDCA1, and KIF20A, as targets for vaccination against lung cancer” NCT01950156 ↗ |